Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial
Capricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In a
comments(0)
5-min edit window · permanent after that